Ovitrelle
BRCA2-Related Cancer Predisposition
University Hospital, Ghentprotein_peptidePhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 81/ 100
Competitive context
27 Active assets in the BRCA2-Related Cancer Predisposition cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Veliparib The University of Texas Health Science Center at San Antonio | Phase 2 | BB |
Talazoparib Brown University | Phase 3 | BB |
Olaparib GBG Forschungs GmbH | Phase 3 | BB |
Letrozole UNICANCER | Phase 3 | BB |
Niraparib Qian Qin | Phase 3 | BB |
View all 44 →
Same molecule, other indications
Ovitrelle is also rated in:
breast-ovarian cancer, familial, susceptibility to, 1Dormant
BB
Indicative · Phase 4
65 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →